Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
16 hedge funds and large institutions have $8.1M invested in Medicenna Therapeutics Corp. Common Shares in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$4.02M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1M |
| 3 |
Renaissance Technologies
New York
|
+$925K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$639K |
| 5 |
VA
VR Adviser
New York
|
+$372K |
Top Sellers
MDNA Hedge Fund Activity: Q3 2020 in Review
16 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q3 2020, worth a combined $8.1M.
Buyers outnumbered sellers: 16 funds opened new MDNA positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $4.02M.
- 16 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $8.1M of Medicenna Therapeutics Corp. Common Shares stock for Q3 2020.
- 16 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q3 2020 and 0 closed out, a net change of +16 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q3 2020 was AWM Investment Company, an estimated $4.02M added.
Based on aggregated 13F filings for Q3 2020.